We are working on several R&D projects to address unmet medical needs. We are interested in collaborating with you if you a have great idea to develop or improve some of the unmet medical needs. Our expertise is in monoclonal antibodies and recombinant proteins. Please contact us to discuss or for more information.
Current Projects Under Development
PriME, Protective Immune Modulation of Effector Function
Impaired immunity due to poor immune effector function is responsible for majority of mortality associated with respiratory diseases, including Covid-19. We have identified a panel of molecules for measuring impaired immune effector functions and tools to modulate a protective immune response, which we call Protective Immune Modulation Mechanism for Augmented Effector functions (PriME). Once validated we believe, can reduce mortality associated with many infectious and metabolic respiratory diseases. Augmenting body’s own immune defense against invading infection is better than treatment of the symptoms.
AINS, Anti-infective Nanoparticles for Protection from Respiratory Infections
Lung is constantly exposed on microorganisms in the air. The first level of protection in lung alveoli is provided by the mucus produced by alveolar cells, which prevent invasion of cells by any pathogens by producing anti infective peptides and surfactants proteins. Although in majority of infections this first line of defense works, for many elderly and immune challenged individuals this level of protection is impaired and causes disease. A good example is with Covid19 where as much as 80 percent increase incidence is seen in the elderly over 60 years of age. In order to improve the health of those with lung infections stemming from medical conditions such has Acute Respiratory Distress Syndrome (ARDS), Chronic Obstructive Pulmonary Disease (COPD), Asthma, Cystic Fibrosis, Sepsis, etc. we have identified and now developing a novel Anti-Infective Nanoparticle based on Lipoprotein Surfactant (AINS) matrix. AINS mimics natural mucus substances in our lungs and helps provide additional protection for people with impaired lung defense mechanism.
Covid-19 Diagnostics and Therapeutics
Sars-CoV-2 infection has become of major pandemic and could last as much as 2 years with local recurrences. So far there is no treatment available. Vaccine in development are at least a year away. We are developing a series of monoclonal antibodies to various targets on the viral proteins. We hope to develop these antibody reagents into diagnostics and therapeutics including for virus neutralization.